23 results about "Calprotectin" patented technology

The invention provides a calprotectin and slgA combined judgment child digestive state evaluation method and system, and relates to the technical field of data detection.The method comprises the steps that the age of a target child is collected, baseline calprotectin and baseline slgA are configured, and a baseline error coefficient is obtained; collecting body characteristics of the target child and a feeding characteristic sequence in a recent preset time range, configuring a physical sign correction coefficient and a feeding correction coefficient, and correcting to obtain a corrected baseline error coefficient; performing calprotectin and slgA fluctuation prediction according to the feeding characteristic sequence to obtain predicted fluctuation calprotectin and predicted fluctuation slgA, and calculating actual calprotectin and actual slgA; and calculating the fluctuation coefficient of predicted fluctuation calprotectin and predicted fluctuation slgA and the fluctuation coefficient of baseline calprotectin and baseline slgA, calculating to obtain data confidence, labeling, and evaluating the digestive state of children. The technical problem that in the prior art, the accuracy of child digestion state evaluation results is insufficient is solved.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The disclosure relates to a point-of-care test device for diagnosis and detection of bacterial infections and hidden septic processes in samples of bodily fluids of premature and newborns comprising a quantitative or semi-quantitative lateral flow immunoassay unit adapted for parallel detection of proteins of the S100 family and for several detection of increased amounts of S100A12 and calprotectin in blood, serum, plasma, and saliva.

The invention provides a whole blood treatment agent, a kit and application of the whole blood treatment agent in detection of calprotectin, and relates to the technical field of in-vitro detection, the whole blood treatment agent comprises 5-15 mmoL / ml of ammonium chloride or 0.01-0.05 mg / ml of ascorbic acid oxidase, and a solvent is an enzyme diluent. The enzyme diluent is used as a solvent, so that the whole blood treatment agent maintains a stable environment in a sample treatment process, and related enzyme activity is maintained. Ammonium chloride promotes erythrocyte lysis to release hemoglobin; ascorbic acid oxidase can catalyze ascorbic acid to be oxidized into dehydroascorbic acid, and interference factors are reduced. By using the whole blood treatment agent, a tedious pretreatment step on a whole blood sample by using a sample treatment liquid is not needed, the directly collected whole blood sample can be used for subsequent detection after being mixed with the whole blood treatment agent, and the directly collected whole blood sample can be used for subsequent detection, so that the sample treatment is simplified, and the risk of introducing an error due to the sample treatment is reduced; a detection result accords with a clinical diagnosis result, and the accuracy is high.

The present invention relates to a CXCR4 inhibitor compound for use in the treatment of a severe acute respiratory distress syndrome (sARDS), wherein the sARDS is characterized by a dysregulation of NETosis which may be measured by the plasmatic levels of cDNA, citrullinated histone H3, neutrophil elastase, interleukin-8, myeloperoxidase-DNA complexes and / or calprotectin. The present invention also relates to a method of prognostic of severe ARDS, a pharmaceutical composition for use in the treatment of severe acute respiratory distress syndrome (ARDS), a kit of prognostic of severe ARDS in a subject and the use of NETosis biomarkers.

The invention discloses a detection kit for detecting calprotectin in human excrement, the detection kit is composed of a sample diluent and detection test paper, the detection test paper is composed of a bottom plate, a nitrocellulose membrane, a conjugate pad, a sample pad and absorbent paper, the absorbent paper, the nitrocellulose membrane, the conjugate pad and the sample pad are sequentially overlapped on the bottom plate, a shell is arranged outside the detection test paper, and the shell is connected with the sample pad. An observation window and a sample adding hole are formed in the shell, and the position of the observation window is matched with the position of the nitrocellulose membrane; the position of the sample adding hole is matched with the position of the sample pad; the nitrocellulose membrane is sequentially provided with a T1 detection line coated with an anti-calprotectin monoclonal antibody, a T2 detection line coated with an anti-calprotectin monoclonal antibody and a quality control line C coated with a goat anti-chicken IgY antibody and / or a goat anti-mouse IgG antibody; a calprotectin monoclonal antibody marked by colloidal gold is solidified on the combination pad, and the sample diluent is prepared from sodium chloride, EDTA (Ethylene Diamine Tetraacetic Acid), PEG (Polyethylene Glycol) 20000, Proclin-300 and purified water.

The invention discloses a detection kit for detecting the content of calprotectin in synovial fluid. The detection kit comprises a detection kit shell and a calprotectin immunochromatography test strip, and the calprotectin immunochromatography test strip is arranged in the detection kit shell; the calprotectin immunochromatography test strip comprises a sample pad, a glass fiber combination pad, a coated nitrocellulose membrane and a water absorption pad which are bonded in sequence, an anti-calprotectin antibody marked by colloidal gold is embedded in the glass fiber combination pad and is used for being combined with calprotectin in a sample to be detected to form a compound; the anti-calprotectin monoclonal antibody is coated on a detection line of the nitrocellulose membrane, and the anti-mouse IgG antibody is coated on a quality control line of the nitrocellulose membrane; the colloidal gold labeled anti-calprotectin antibody is embedded in the glass fiber cushion layer, and the image recognition module is used for collecting a tested test paper image and calculating a relative gray value of a detection line and a quality control line, so that a calprotectin concentration interval is judged.

A joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads (2) of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines (3) of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.

1. The name of the design product: packaging box (vaginitis combination, calprotectin, lactoferrin, transferrin, fecal occult blood). 2. The use of the design product: for packaging. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: design 1 front view. 5. Design 1 is designated as the basic design.

This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension.

The application provides an anti-calprotectin monoclonal antibody combination and application thereof. The anti-calprotectin monoclonal antibody combination comprises a first antibody and a second antibody, wherein the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region; the amino acid sequence of the first light chain variable region comprises VL-CDR1-3 shown in SEQ ID NO:1-3; the amino acid sequence of the first heavy chain variable region comprises VH-CDR1-3 shown in SEQ ID NO:4-6; the amino acid sequence of the second light chain variable region comprises VL-CDR1-3 shown in SEQ ID NO:7-9; and the amino acid sequence of the second heavy chain variable region comprises VH-CDR1-3 shown in SEQ ID NO:10-12. The anti-calprotectin monoclonal antibody combination can improve the sensitivity and accuracy of in-vitro detection.

This invention relates to HeartTAC, an antibody protein that targets and degrades calprotectin, and its applications, belonging to the field of biomedical technology. This invention provides HeartTAC, an antibody protein that targets and degrades calprotectin, the amino acid sequence of which is shown in SEQ ID NO. 6 or SEQ ID NO. 4. This invention employs an extracellular targeted protein degradation scheme to construct HeartTAC, an antibody protein that targets and degrades calprotectin. This protein exhibits good targeting specificity to the heart, can degrade calprotectin in the heart, can significantly improve cardiac function, alleviate cardiac fibrosis, and has good safety profile. It opens up an important new direction for the prevention and control of cardiovascular diseases and has promising application prospects.

The invention relates to peptides capable of binding calprotectin. The invention is further directed to methods of detecting and purifying calprotectin.

The invention relates to lactobacillus casei LC189 capable of inhibiting intestinal pathogenic bacteria and application of the lactobacillus casei LC189 capable of inhibiting the intestinal pathogenic bacteria, the lactobacillus casei capable of inhibiting the intestinal pathogenic bacteria is named as a lactobacillus casei LC189 strain, the preservation number is GDMCC No: 63092, and the preservation date is December 26, 2022. A novel lactobacillus casei strain with the effect of inhibiting enteropathogenic bacteria is separated from intestinal mucosa of a healthy sow and is preserved, the strain can inhibit the enteropathogenic bacteria such as escherichia coli, salmonella and staphylococcus aureus, and also can maintain the intestinal health of animals, and the specific expression is as follows: the diarrhea rate of piglets is reduced; the content of ammonia gas and methyl mercaptan in the excrement is reduced, and the pH value of the excrement returns to normal from a weak acid environment; beneficial bacteria are promoted to colonize in intestinal tracts, and the number of the beneficial bacteria is increased; the content of calprotectin in excrement is reduced, the inflammation level in the intestinal tract is reduced, and the intestinal tract health is promoted.

The utility model discloses a special sample extraction test tube for calprotectin, which comprises a tube body with two open ends; the sampling rod is coaxially inserted into the pipe body, and the tail end of the sampling rod extends out of one end of the pipe body and is detachably connected with the end; the tube cover is detachably connected with the other end of the tube body, the tube cover comprises a first cover body and a second cover body, filter cotton is arranged in the first cover body, the second cover body is detachably arranged on the first cover body, and a dripping hole is formed in the top of the first cover body. According to the sample extraction test tube, the first cover body and the second cover body which are detachably arranged as well as the filter cotton arranged on the first cover body are adopted, so that the sample extraction test tube has the characteristics of different detection instruments, medical personnel do not need to prepare different sample extraction devices for different instruments, and the complexity and the cost of operation are reduced.

This invention provides a method for synthesizing, purifying, and applying a calprotectin fusion protein, belonging to the field of molecular biology. The calprotectin fusion protein of this invention is a heterodimer or heterotetramer formed by the polymerization of the S100A8 and S100A9 subunits, with a six-histidine affinity tag introduced at the amino terminus of the S100A8 subunit. This invention enables the simultaneous synthesis of both the S100A8 and S100A9 subunits of calprotectin using a single recombinant *E. coli* strain. The two subunits can self-assemble calprotectin within the bacterial cell, eliminating the step of artificially mixing subunit solutions in existing microbial fermentation synthesis methods. Furthermore, by introducing a six-histidine affinity tag at the amino terminus of the S100A8 subunit, this invention facilitates the purification of the calprotectin fusion protein, improving production efficiency and product purity. The calprotectin fusion protein of this invention retains the transcriptional regulatory activity of natural calprotectin in *E. coli*.

The utility model provides an excrement calprotectin detection appliance which comprises a transparent sample dilution container, a transparent sealing cover and a detection plate, a sampler is detachably mounted in the transparent sample dilution container through the transparent sealing cover, and the detection plate is rotatably mounted outside the transparent sealing cover; due to the integral arrangement, when in use, diluted sample liquid does not need to drop out of the transparent sample diluting container, can be in contact with the detection card in the detection plate, and can be detected through the detection card, so that the sample liquid can be effectively prevented from leaking, unnecessary pollution and even infection are avoided, and the detection efficiency is improved. Therefore, the whole device is safer and more reliable in the detection process.

Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.

An immunosensor device is disclosed for rapid detection of circulating biomarkers associated with thrombosis, including C-reactive protein (CRP), calprotectin, soluble platelet selectin (sP-selectin), and D-dimer. The immunosensors were fabricated using fiber-laser engraving of carbon nanotubes and CO2-laser cutting of microfluidic channels and features, along with the electrochemical deposition of gold nanoparticles to conjugate with biomarker-specific aptamers and antibody. Using unsupervised clustering based on 4-biomarker concentrations, thrombotic events were predicted in 49 of 53 patients. The 4-biomarker combination yielded an area under the receiver operating characteristic curve (AUC) of 0.95, demonstrating high sensitivity and specificity for acute thrombosis prediction compared to the AUC values for individual biomarker: CRP (0.773), calprotectin (0.711), sP-selectin (0.683), and D-dimer (0.739). The immunosensor device with unsupervised clustering provides accurate and efficient methods for predicting thrombosis, guiding personalized medicine.

The invention provides an intestinal tract risk assessment method and system and a storage medium, and the method comprises the steps: firstly obtaining basic biological information, a drug type and a drug dosage, predicting the total defecation times needed for gut purge, and carrying out the prediction of the total defecation times at different time nodes before and after the preoperative intestinal tract preparation of a patient; detecting markers such as indole concentration, short-chain fatty acid concentration, calprotectin and the like which reflect intestinal flora function states and mucous membrane function states, and analyzing a static risk index, a dynamic risk index and a risk disturbance rate based on the data; and further calculating and analyzing a risk assessment coefficient according to the static risk index, the dynamic risk index and the risk disturbance rate, and finally outputting a risk assessment level based on the risk assessment coefficient. Compared with the prior art, the technical scheme has the beneficial effects that the medicine action effect is judged in time, so that the technical purposes of protecting the intestinal microecosystem and fully cleaning the intestinal tract are achieved.

The invention discloses an anti-panda calprotectin monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibodies. According to the invention, a panda calprotectin expression vector is constructed, a high-yield recombinant protein is obtained by using a pichia pastoris expression system, and the high-yield recombinant protein is used as an immunogen to immunize a mouse to obtain the anti-panda calprotectin monoclonal antibody. Furthermore, based on a colloidal gold immunochromatography technology, the first non-invasive kit for rapidly detecting calprotectin in a panda excrement sample is established, and the kit is suitable for non-invasive inflammation monitoring of pandas in scenes such as natural reserves, zoos and field scientific investigation; the method is of great significance in monitoring and screening intestinal diseases of wild and captive pandas.

The invention provides an anti-calprotectin monoclonal antibody combination and application thereof.The anti-calprotectin monoclonal antibody combination comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region; wherein the amino acid sequence of the first light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 1-3; the amino acid sequence of the first heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 4-6; the amino acid sequence of the second light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 7-9; and the amino acid sequence of the second heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 10-12. The anti-calprotectin monoclonal antibody combination can improve the sensitivity and accuracy of in-vitro detection.